Abstract
An experimental study was performed to evaluate the efficacy of BMAP-28 alone and in combination with vancomycin in animal models ureteral stent infection due to Enterococcus faecalis and Staphylococcus aureus. Study included a control group without bacterial challenge to evaluate the sterility of surgical procedure, a challenged control group that did not receive any antibiotic prophylaxis and for each bacterial strain three challenged groups that received (a) 10 mg/kg vancomycin intraperitoneally, immediately after stent implantation, (b) BMAP-28-coated ureteral stents where 0.2-cm2 sterile ureteral stents were incubated in 1 mg/l BMAP-28 solution for 30 min immediately before implantation and (c) intraperitoneal vancomycin plus BMAP-28-coated ureteral stent at the above concentrations. Experiments were performed in duplicate. Ureteral stents were explanted at day 5 following implantation and biofilm bacteria enumerated. Our data showed that rats that received intraperitoneal vancomycin showed the lowest bacterial numbers. BMAP-28 combined with vancomycin showed efficacies higher than that of each single compound. These results highlight the potential usefulness of this combination in preventing ureteral stent-associated in gram-positive infections.
| Original language | English |
|---|---|
| Pages (from-to) | 1118-1123 |
| Number of pages | 6 |
| Journal | Peptides |
| Volume | 29 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2008 |
Fingerprint
Keywords
- Animal model
- Biofilm
- Cathelicidins
- Gram-positive cocci
- Ureteral stent
ASJC Scopus subject areas
- Biochemistry
- Endocrinology
- Physiology
- Cellular and Molecular Neuroscience
Cite this
BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection. / Orlando, Fiorenza; Ghiselli, Roberto; Cirioni, Oscar; Minardi, Daniele; Tomasinsig, Linda; Mocchegiani, Federico; Silvestri, Carmela; Skerlavaj, Barbara; Riva, Alessandra; Muzzonigro, Giovanni; Saba, Vittorio; Scalise, Giorgio; Zanetti, Margherita; Giacometti, Andrea.
In: Peptides, Vol. 29, No. 7, 07.2008, p. 1118-1123.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - BMAP-28 improves the efficacy of vancomycin in rat models of gram-positive cocci ureteral stent infection
AU - Orlando, Fiorenza
AU - Ghiselli, Roberto
AU - Cirioni, Oscar
AU - Minardi, Daniele
AU - Tomasinsig, Linda
AU - Mocchegiani, Federico
AU - Silvestri, Carmela
AU - Skerlavaj, Barbara
AU - Riva, Alessandra
AU - Muzzonigro, Giovanni
AU - Saba, Vittorio
AU - Scalise, Giorgio
AU - Zanetti, Margherita
AU - Giacometti, Andrea
PY - 2008/7
Y1 - 2008/7
N2 - An experimental study was performed to evaluate the efficacy of BMAP-28 alone and in combination with vancomycin in animal models ureteral stent infection due to Enterococcus faecalis and Staphylococcus aureus. Study included a control group without bacterial challenge to evaluate the sterility of surgical procedure, a challenged control group that did not receive any antibiotic prophylaxis and for each bacterial strain three challenged groups that received (a) 10 mg/kg vancomycin intraperitoneally, immediately after stent implantation, (b) BMAP-28-coated ureteral stents where 0.2-cm2 sterile ureteral stents were incubated in 1 mg/l BMAP-28 solution for 30 min immediately before implantation and (c) intraperitoneal vancomycin plus BMAP-28-coated ureteral stent at the above concentrations. Experiments were performed in duplicate. Ureteral stents were explanted at day 5 following implantation and biofilm bacteria enumerated. Our data showed that rats that received intraperitoneal vancomycin showed the lowest bacterial numbers. BMAP-28 combined with vancomycin showed efficacies higher than that of each single compound. These results highlight the potential usefulness of this combination in preventing ureteral stent-associated in gram-positive infections.
AB - An experimental study was performed to evaluate the efficacy of BMAP-28 alone and in combination with vancomycin in animal models ureteral stent infection due to Enterococcus faecalis and Staphylococcus aureus. Study included a control group without bacterial challenge to evaluate the sterility of surgical procedure, a challenged control group that did not receive any antibiotic prophylaxis and for each bacterial strain three challenged groups that received (a) 10 mg/kg vancomycin intraperitoneally, immediately after stent implantation, (b) BMAP-28-coated ureteral stents where 0.2-cm2 sterile ureteral stents were incubated in 1 mg/l BMAP-28 solution for 30 min immediately before implantation and (c) intraperitoneal vancomycin plus BMAP-28-coated ureteral stent at the above concentrations. Experiments were performed in duplicate. Ureteral stents were explanted at day 5 following implantation and biofilm bacteria enumerated. Our data showed that rats that received intraperitoneal vancomycin showed the lowest bacterial numbers. BMAP-28 combined with vancomycin showed efficacies higher than that of each single compound. These results highlight the potential usefulness of this combination in preventing ureteral stent-associated in gram-positive infections.
KW - Animal model
KW - Biofilm
KW - Cathelicidins
KW - Gram-positive cocci
KW - Ureteral stent
UR - http://www.scopus.com/inward/record.url?scp=44649096832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44649096832&partnerID=8YFLogxK
U2 - 10.1016/j.peptides.2008.03.005
DO - 10.1016/j.peptides.2008.03.005
M3 - Article
C2 - 18430491
AN - SCOPUS:44649096832
VL - 29
SP - 1118
EP - 1123
JO - Peptides
JF - Peptides
SN - 0196-9781
IS - 7
ER -